Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All colchicine studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchColchicineColchicine (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality 67% Improvement Relative Risk Recovery 63% Colchicine  Gorial et al.  LATE TREATMENT  RCT Is late treatment with colchicine beneficial for COVID-19? RCT 160 patients in Iraq Improved recovery with colchicine (p=0.001) c19early.org Gorial et al., Annals of Medicine and .., Apr 2022 Favors colchicine Favors control

Randomized controlled trial of colchicine add on to the standard therapy in moderate and severe corona virus Disease-19 infection

Gorial et al., Annals of Medicine and Surgery, doi:10.1016/j.amsu.2022.103593
Apr 2022  
  Post
  Facebook
Share
  Source   PDF   All   Meta
Colchicine for COVID-19
5th treatment shown to reduce risk in September 2020
 
*, now known with p = 0.0000001 from 54 studies.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,100+ studies for 60+ treatments. c19early.org
RCT with 80 colchicine and 80 control patients, showing improved recovery with treatment. SOC included vitamin C, vitamin D, and zinc.
risk of death, 66.7% lower, RR 0.33, p = 0.62, treatment 1 of 80 (1.2%), control 3 of 80 (3.8%), NNT 40.
risk of no recovery, 62.8% lower, HR 0.37, p < 0.001, treatment 80, control 80, inverted to make HR<1 favor treatment, Cox proportional hazards.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Gorial et al., 12 Apr 2022, Randomized Controlled Trial, Iraq, peer-reviewed, 6 authors, dosage 1mg days 1-7, 0.5mg days 8-15.
This PaperColchicineAll
Randomized controlled trial of colchicine add on to the standard therapy in moderate and severe corona virus Disease-19 infection
Faiq I Gorial, Mohammed Fauzi Maulood, Ahmed S Abdulamir, Ahmed Sameer Alnuaimi, Manal K Abdulrrazaq, Fadil Agla Bonyan
Annals of Medicine and Surgery, doi:10.1016/j.amsu.2022.103593
This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Conflict of interest statement None. Trial registry number
References
Brunetti, Diawara, Tsai, Colchicine to weather the cytokine storm in hospitalized patients with COVID-19, J Clin Med
Da, Roura-Piloto, Moral-Escudero, Colchicine in Recently Hospitalized Patients with COVID-19: A Randomized Controlled Trial (COL-COVID), Int J Gen Med, doi:10.2147/IJGM.S329810
Deftereos, Giannopoulos, Vrachatis, Effect of colchicine vs standard care on cardiac and inflammatory biomarkers and clinical outcomes in patients J o u r n a l P r e -p r o o f hospitalized with coronavirus disease 2019: the GRECCO-19 randomized clinical trial, JAMA Netw Open
Faigenbaum, June, Cytokine storm, N Engl J Med
Horby, Landrain, Low-cost dexamethasone reduces death by up to one third in hospitalised patients with severe respiratory complications of COVID-19
Jackman, Rhoads, Cornwell, Kandarian, Microtubule-mediated NF-kappaB activation in the TNF-alpha signaling pathway, Exp Cell Res
Laujwy, Rosin, Agha, The CONSORT (CONsolidated standards of reporting trials) 2010 guideline, Int. J. Surg
Lopes, Bonjorno, Giannini, Beneficial effects of colchicine for moderate to severe COVID-19: a randomised, double-blinded, placebo-controlled clinical trial RMD Open, doi:10.1136/rmdopen-2020-001455
Nieto-Torres, Verdiá-Báguena, Jimenez-Guardeno, Severe acute respiratory syndrome coronavirus E protein transports calcium ions and activates the NLRP3 inflammasome, Virology
Reyes, Hu, Teperman, Anti-inflammatory therapy for COVID19 infection: the case for colchicine, Ann Rheum Dis
Richter, Boldescu, Graf, Synthesis, biological evaluation, and molecular docking of combretastatin and colchicine derivatives and their hCE1-activated prodrugs as antiviral agents, ChemMedChem
Salehzadeh, Pourfarzi, Ataei, The impact of colchicine on the COVID-19 patients; a clinical trial
Sandhu, Tieng, Chilimuri, Franchin, A case control study to evaluate the impact of colchicine on patients admitted to the hospital with moderate to severe COVID-19 infection, Can J Infect Dis Med Microbiol
Schlesinger, Firestein, Brunetti, Colchicine in COVID-19: an old drug, new use, Curr Pharmacol Rep
Tardif, Bouabdallaoui, Allier, Colchicine for community-treated patients with COVID19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial, Lancet Respir Med
Vrachatis, Giannopoulos, Giotaki, Impact of colchicine on mortality in patients with COVID-19. A metaanalysis, Hellenic J Cardiol
Wu, Chen, Cai, Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China, JAMA Intern Med. Published online, doi:10.1001/jamainternmed.2020.0994
Ye, Wang, Mao, The pathogenesis and treatment of the `Cytokine Storm' in COVID-19, J Infect, doi:10.1016/j.jinf.2020.03.037
Yu, Du, Ojcius, Measures for diagnosing and treating infections bya novel coronavirus responsible for a pneumonia outbreak originating in Wuhan
{ 'DOI': '10.1016/j.amsu.2022.103593', 'ISSN': ['2049-0801'], 'URL': 'http://dx.doi.org/10.1016/j.amsu.2022.103593', 'alternative-id': ['S2049080122003533'], 'article-number': '103593', 'author': [ { 'ORCID': 'http://orcid.org/0000-0002-2760-5566', 'affiliation': [], 'authenticated-orcid': False, 'family': 'Gorial', 'given': 'Faiq I.', 'sequence': 'first'}, {'affiliation': [], 'family': 'Maulood', 'given': 'Mohammed Fauzi', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Abdulamir', 'given': 'Ahmed S.', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Alnuaimi', 'given': 'Ahmed Sameer', 'sequence': 'additional'}, {'affiliation': [], 'family': 'abdulrrazaq', 'given': 'Manal K.', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Bonyan', 'given': 'Fadil Agla', 'sequence': 'additional'}], 'container-title': ['Annals of Medicine and Surgery'], 'content-domain': {'crossmark-restriction': False, 'domain': []}, 'created': {'date-parts': [[2022, 4, 10]], 'date-time': '2022-04-10T05:19:07Z', 'timestamp': 1649567947000}, 'deposited': { 'date-parts': [[2022, 4, 10]], 'date-time': '2022-04-10T05:19:20Z', 'timestamp': 1649567960000}, 'indexed': {'date-parts': [[2022, 4, 10]], 'date-time': '2022-04-10T05:41:10Z', 'timestamp': 1649569270417}, 'is-referenced-by-count': 0, 'issn-type': [{'type': 'print', 'value': '2049-0801'}], 'issued': {'date-parts': [[2022, 4]]}, 'language': 'en', 'license': [ { 'URL': 'https://www.elsevier.com/tdm/userlicense/1.0/', 'content-version': 'tdm', 'delay-in-days': 0, 'start': { 'date-parts': [[2022, 4, 1]], 'date-time': '2022-04-01T00:00:00Z', 'timestamp': 1648771200000}}, { 'URL': 'http://creativecommons.org/licenses/by/4.0/', 'content-version': 'vor', 'delay-in-days': 2, 'start': { 'date-parts': [[2022, 4, 3]], 'date-time': '2022-04-03T00:00:00Z', 'timestamp': 1648944000000}}], 'link': [ { 'URL': 'https://api.elsevier.com/content/article/PII:S2049080122003533?httpAccept=text/xml', 'content-type': 'text/xml', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://api.elsevier.com/content/article/PII:S2049080122003533?httpAccept=text/plain', 'content-type': 'text/plain', 'content-version': 'vor', 'intended-application': 'text-mining'}], 'member': '78', 'original-title': [], 'page': '103593', 'prefix': '10.1016', 'published': {'date-parts': [[2022, 4]]}, 'published-print': {'date-parts': [[2022, 4]]}, 'publisher': 'Elsevier BV', 'reference': [ { 'article-title': 'Risk factors associated with acute respiratory distress syndrome and ' 'death in patients with coronavirus disease 2019 pneumonia in Wuhan, ' 'China', 'author': 'Wu', 'journal-title': 'JAMA Intern. Med.', 'key': '10.1016/j.amsu.2022.103593_bib1', 'volume': '13', 'year': '2020'}, { 'author': 'World Health Organization', 'key': '10.1016/j.amsu.2022.103593_bib2', 'series-title': 'Emergencies', 'year': '2020'}, { 'DOI': '10.1016/j.micinf.2020.01.003', 'article-title': 'Measures for diagnosing and treating infections bya novel coronavirus ' 'responsible for a pneumonia outbreak originating in Wuhan, China[J]', 'author': 'Yu', 'doi-asserted-by': 'crossref', 'journal-title': 'Microb. Infect.', 'key': '10.1016/j.amsu.2022.103593_bib3', 'year': '2020'}, { 'DOI': '10.1056/NEJMra2026131', 'article-title': 'Cytokine storm', 'author': 'Faigenbaum', 'doi-asserted-by': 'crossref', 'first-page': '2255', 'journal-title': 'N. Engl. J. Med.', 'key': '10.1016/j.amsu.2022.103593_bib4', 'volume': '383', 'year': '2020'}, { 'DOI': '10.1016/j.virol.2015.08.010', 'article-title': 'Severe acute respiratory syndrome coronavirus E protein transports ' 'calcium ions and activates the NLRP3 inflammasome', 'author': 'Nieto-Torres', 'doi-asserted-by': 'crossref', 'first-page': '330', 'journal-title': 'Virology', 'key': '10.1016/j.amsu.2022.103593_bib5', 'volume': '485', 'year': '2015'}, { 'DOI': '10.1007/s40495-020-00225-6', 'article-title': 'Colchicine in COVID-19: an old drug, new use', 'author': 'Schlesinger', 'doi-asserted-by': 'crossref', 'first-page': '137', 'journal-title': 'Curr. Pharmacol. Rep.', 'key': '10.1016/j.amsu.2022.103593_bib6', 'volume': '6', 'year': '2020'}, { 'DOI': '10.1016/j.yexcr.2009.08.020', 'article-title': 'Microtubule-mediated NF-kappaB activation in the TNF-alpha signaling ' 'pathway', 'author': 'Jackman', 'doi-asserted-by': 'crossref', 'first-page': '3242', 'journal-title': 'Exp. Cell Res.', 'key': '10.1016/j.amsu.2022.103593_bib7', 'volume': '315', 'year': '2009'}, { 'DOI': '10.1002/cmdc.201800641', 'article-title': 'Synthesis, biological evaluation, and molecular docking of ' 'combretastatin and colchicine derivatives and their hCE1-activated ' 'prodrugs as antiviral agents', 'author': 'Richter', 'doi-asserted-by': 'crossref', 'first-page': '469', 'journal-title': 'ChemMedChem', 'key': '10.1016/j.amsu.2022.103593_bib8', 'volume': '14', 'year': '2019'}, { 'DOI': '10.1001/jamanetworkopen.2020.13136', 'article-title': 'Effect of colchicine vs standard care on cardiac and inflammatory ' 'biomarkers and clinical outcomes in patients hospitalized with ' 'coronavirus disease 2019: the GRECCO-19 randomized clinical trial', 'author': 'Deftereos', 'doi-asserted-by': 'crossref', 'journal-title': 'JAMA Netw. Open', 'key': '10.1016/j.amsu.2022.103593_bib9', 'volume': '3', 'year': '2020'}, { 'DOI': '10.1016/j.hjc.2020.11.012', 'article-title': 'Impact of colchicine on mortality in patients with COVID- 19. A ' 'meta-analysis', 'author': 'Vrachatis', 'doi-asserted-by': 'crossref', 'journal-title': 'Hellenic J. Cardiol.', 'key': '10.1016/j.amsu.2022.103593_bib10', 'year': '2021'}, { 'key': '10.1016/j.amsu.2022.103593_bib11', 'unstructured': 'LauJWY, D. Rosin, R. Agha, et al., The CONSORT (CONsolidated standards ' 'of reporting trials) 2010 guideline, Int. J. Surg.. (September 2021) 93. ' 'Avaialble ' 'online:http://www.journal-surgery.net/article/S1743-9191%2811%2900565-6/fulltext.'}, { 'author': 'World Health Organization', 'key': '10.1016/j.amsu.2022.103593_bib12', 'series-title': 'Clinical Management of COVID-19: Interim Guidance', 'year': '2020'}, { 'DOI': '10.1056/NEJMoa2023184', 'article-title': 'Repurposed antiviral drugs for COVID-19—interim WHO SOLIDARITY trial ' 'results', 'doi-asserted-by': 'crossref', 'first-page': '497', 'issue': '6', 'journal-title': 'N. Engl. J. Med.', 'key': '10.1016/j.amsu.2022.103593_bib13', 'volume': '384', 'year': '2021'}, { 'DOI': '10.1016/j.jinf.2020.03.037', 'article-title': "The pathogenesis and treatment of the `Cytokine Storm' in COVID-19", 'author': '13.Ye', 'doi-asserted-by': 'crossref', 'first-page': '607', 'issue': '6', 'journal-title': 'J. Infect.', 'key': '10.1016/j.amsu.2022.103593_bib14', 'volume': '80', 'year': '2020'}, { 'author': 'Horby', 'key': '10.1016/j.amsu.2022.103593_bib15', 'series-title': 'Low-cost Dexamethasone Reduces Death by up to One Third in Hospitalised ' 'Patients with Severe Respiratory Complications of COVID-19', 'year': '2020'}, { 'DOI': '10.1136/annrheumdis-2020-219174', 'article-title': 'Anti-inflammatory therapy for COVID19 infection: the case for ' 'colchicine', 'author': 'Reyes', 'doi-asserted-by': 'crossref', 'first-page': '550', 'issue': '5', 'journal-title': 'Ann. Rheum. Dis.', 'key': '10.1016/j.amsu.2022.103593_bib16', 'volume': '80', 'year': '2021'}, { 'DOI': '10.1016/S2213-2600(21)00435-5', 'article-title': 'Colchicine in patients admitted to hospital with COVID19 (RECOVERY): a ' 'randomised, controlled, open-label, platform trial', 'doi-asserted-by': 'crossref', 'first-page': '1419', 'issue': '12', 'journal-title': 'Lancet Respir. Med.', 'key': '10.1016/j.amsu.2022.103593_bib17', 'volume': '9', 'year': '2021'}, { 'DOI': '10.2147/IJGM.S329810', 'article-title': 'Colchicine in recently hospitalized patients with COVID-19: a ' 'randomized controlled trial (COL-COVID)', 'author': 'Pascual-Figal', 'doi-asserted-by': 'crossref', 'first-page': '5517', 'journal-title': 'Int. J. Gen. Med.', 'key': '10.1016/j.amsu.2022.103593_bib18', 'volume': '14', 'year': '2021'}, { 'DOI': '10.1136/rmdopen-2020-001455', 'article-title': 'Beneficial effects of colchicine for moderate to severe COVID-19: a ' 'randomised, double-blinded, placebo-controlled clinical trial', 'author': 'Lopes', 'doi-asserted-by': 'crossref', 'journal-title': 'RMD Open', 'key': '10.1016/j.amsu.2022.103593_bib19', 'volume': '7', 'year': '2021'}, { 'DOI': '10.1016/S2213-2600(21)00222-8', 'article-title': 'Colchicine for community-treated patients with COVID19 (COLCORONA): a ' 'phase 3, randomised, double-blinded, adaptive, placebo-controlled, ' 'multicentre trial', 'author': 'Tardif', 'doi-asserted-by': 'crossref', 'first-page': '924', 'issue': '8', 'journal-title': 'Lancet Respir. Med.', 'key': '10.1016/j.amsu.2022.103593_bib20', 'volume': '9', 'year': '2021'}, { 'DOI': '10.3390/jcm9092961', 'article-title': 'Colchicine to weather the cytokine storm in hospitalized patients with ' 'COVID-19', 'author': 'Brunetti', 'doi-asserted-by': 'crossref', 'issue': '9', 'journal-title': 'J. Clin. Med.', 'key': '10.1016/j.amsu.2022.103593_bib21', 'volume': '9', 'year': '2020'}, { 'DOI': '10.1155/2020/8865954', 'article-title': 'A case control study to evaluate the impact of colchicine on patients ' 'admitted to the hospital with moderate to severe COVID-19 infection', 'author': 'Sandhu', 'doi-asserted-by': 'crossref', 'journal-title': 'Can. J. Infect Dis. Med. Microbiol.', 'key': '10.1016/j.amsu.2022.103593_bib22', 'year': '2020'}, { 'author': 'Salehzadeh', 'key': '10.1016/j.amsu.2022.103593_bib23', 'series-title': 'The Impact of Colchicine on the COVID-19 Patients; a Clinical Trial. ' 'Research Square', 'year': '2020'}, { 'key': '10.1016/j.amsu.2022.103593_bib24', 'unstructured': 'CCOVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 ' '(COVID-19) Treatment Guidelines. National Institutes of Health. ' 'Available at https://www.covid19treatmentguidelines.nih.gov/. accessed ' 'at 05/01/2022'}], 'reference-count': 24, 'references-count': 24, 'relation': {}, 'resource': {'primary': {'URL': 'https://linkinghub.elsevier.com/retrieve/pii/S2049080122003533'}}, 'score': 1, 'short-container-title': ['Annals of Medicine and Surgery'], 'short-title': [], 'source': 'Crossref', 'subject': ['General Medicine', 'Surgery'], 'subtitle': [], 'title': [ 'Randomized controlled trial of colchicine add on to the standard therapy in moderate and ' 'severe corona virus Disease-19 infection'], 'type': 'journal-article'}
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit